Milestone Pharmaceuticals Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Milestone Pharmaceuticals Inc. | MIST - NASDAQ |
$14.00-$16.00 | $15.00 | $15.61 | 5.5 million | 5/9/2019 |
| Jefferies, Cowen, Piper Jaffray, Oppenheimer & Co. | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-04-12 Terms Added 2019-04-29 | ||||||
Milestone Pharmaceuticals Inc. Quote & Chart - Click for current quote - MIST
IPO Boutique aggregates information on public companies and private companies, such as "MIST" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Milestone Pharmaceuticals Inc. (adapted from Milestone Pharmaceuticals Inc. prospectus):
They are a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "MIST" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.